JP2016511751A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016511751A5 JP2016511751A5 JP2015555353A JP2015555353A JP2016511751A5 JP 2016511751 A5 JP2016511751 A5 JP 2016511751A5 JP 2015555353 A JP2015555353 A JP 2015555353A JP 2015555353 A JP2015555353 A JP 2015555353A JP 2016511751 A5 JP2016511751 A5 JP 2016511751A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- follistatin
- protein
- seq
- recombinant follistatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361756996P | 2013-01-25 | 2013-01-25 | |
| US61/756,996 | 2013-01-25 | ||
| US201361915733P | 2013-12-13 | 2013-12-13 | |
| US61/915,733 | 2013-12-13 | ||
| PCT/US2014/012996 WO2014116981A1 (en) | 2013-01-25 | 2014-01-24 | Follistatin in treating duchenne muscular dystrophy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018203613A Division JP2019059730A (ja) | 2013-01-25 | 2018-10-30 | デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016511751A JP2016511751A (ja) | 2016-04-21 |
| JP2016511751A5 true JP2016511751A5 (enExample) | 2017-02-23 |
| JP6475639B2 JP6475639B2 (ja) | 2019-02-27 |
Family
ID=50159515
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015555353A Expired - Fee Related JP6475639B2 (ja) | 2013-01-25 | 2014-01-24 | デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン |
| JP2018203613A Pending JP2019059730A (ja) | 2013-01-25 | 2018-10-30 | デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018203613A Pending JP2019059730A (ja) | 2013-01-25 | 2018-10-30 | デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9957309B2 (enExample) |
| EP (1) | EP2948161B1 (enExample) |
| JP (2) | JP6475639B2 (enExample) |
| KR (1) | KR102253597B1 (enExample) |
| CN (1) | CN104902915B (enExample) |
| AU (2) | AU2014209178B2 (enExample) |
| CA (1) | CA2898121A1 (enExample) |
| EA (1) | EA201590719A1 (enExample) |
| ES (1) | ES2715710T3 (enExample) |
| IL (1) | IL240024B (enExample) |
| MX (1) | MX362105B (enExample) |
| WO (1) | WO2014116981A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| TW201803890A (zh) | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| CN102131822A (zh) | 2008-06-26 | 2011-07-20 | 阿塞勒隆制药公司 | 进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| EA201590719A1 (ru) * | 2013-01-25 | 2015-12-30 | Шир Хьюман Дженетик Терапис, Инк. | Фоллистатин в лечении мышечной дистрофии дюшенна |
| JP6392315B2 (ja) | 2013-03-14 | 2018-09-19 | イミュソフト コーポレーション | インビトロでのメモリーｂ細胞分化方法およびｖｓｖ−ｇ偽型ウイルスベクターを用いる形質導入方法 |
| US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
| KR102132144B1 (ko) * | 2014-06-04 | 2020-07-09 | 악셀레론 파마 인코포레이티드 | 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물 |
| CN107636154A (zh) * | 2015-03-26 | 2018-01-26 | 阿塞勒隆制药公司 | 促滤泡素抑制素相关的融合蛋白及其用途 |
| CN116196389A (zh) * | 2016-01-06 | 2023-06-02 | 康德生物医疗有限公司 | 用于预防和治疗杜氏肌肉萎缩症的方法和组合物 |
| MA43588A (fr) * | 2016-03-04 | 2021-06-02 | Takeda Pharmaceuticals Co | Protéines de fusion follistatine-fc recombinantes et leur utilisation dans le traitement de la dystrophie musculaire de duchenne |
| JP2020519291A (ja) * | 2017-05-12 | 2020-07-02 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 組み換えフォリスタチン−ｆｃ融合タンパク質およびデュシェンヌ型筋ジストロフィーの治療における使用 |
| KR101822633B1 (ko) * | 2017-08-22 | 2018-01-26 | (주)진셀팜 | 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도 |
| WO2019046903A1 (en) * | 2017-09-08 | 2019-03-14 | Baker Heart and Diabetes Institute | THERAPEUTIC METHOD FOR INCREASING MUSCLE MASS IN A SUBJECT |
| CN111936617A (zh) * | 2018-03-16 | 2020-11-13 | 益缪索夫特公司 | 经遗传工程化以分泌卵泡抑素的b细胞以及使用所述b细胞来治疗卵泡抑素相关的疾病、病况、病症及增强肌肉生长和力量的方法 |
| WO2019191204A1 (en) * | 2018-03-28 | 2019-10-03 | Acceleron Pharma Inc. | Follistatin polypeptides for the treatment of muscle contracture |
| CA3094859A1 (en) * | 2020-10-01 | 2022-04-01 | Entos Pharmaceuticals Inc. | Proteolipid vesicles formulated with fusion associated small transmembrane proteins |
| KR102361657B1 (ko) | 2021-04-26 | 2022-02-14 | 주식회사 케이에스비튜젠 | 14-디옥시-11,12-디디히드로안드로그라폴라이드 석시네이트를 유효성분으로 함유하는 듀센형 근이영양증을 포함한 유전성 근육질환의 예방 또는 치료용 조성물 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| JP4336498B2 (ja) | 2000-12-12 | 2009-09-30 | メディミューン，エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
| JP4429728B2 (ja) | 2002-02-21 | 2010-03-10 | ワイス エルエルシー | フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質 |
| US7355018B2 (en) * | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
| JP4688483B2 (ja) | 2004-04-15 | 2011-05-25 | 株式会社テクノネットワーク四国 | フォリスタチン変異体ポリペプチド |
| US8163881B2 (en) | 2005-05-31 | 2012-04-24 | The Board Of Regents Of The University Of Texas System | Immunoglobulin molecules with improved characteristics |
| WO2008030367A2 (en) * | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Selective myostatin inhibitors |
| CN102131822A (zh) | 2008-06-26 | 2011-07-20 | 阿塞勒隆制药公司 | 进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法 |
| KR20110031951A (ko) * | 2008-06-26 | 2011-03-29 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒｉｉａ의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도 |
| JP6211767B2 (ja) * | 2009-09-09 | 2017-10-11 | アクセルロン ファーマ， インコーポレイテッド | ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 |
| US9023890B2 (en) * | 2009-12-02 | 2015-05-05 | The Charlotte-Mecklenburg Hospital Authority | Nitrate esters and their use for the treatment of muscle and muscle related diseases |
| US8580922B2 (en) | 2011-03-04 | 2013-11-12 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
| MY177331A (en) | 2012-06-15 | 2020-09-12 | Pfizer | Improved antagonist antibodies against gdf-8 and uses therefor |
| HUE043482T2 (hu) | 2012-09-13 | 2019-08-28 | Bristol Myers Squibb Co | Miosztatint megkötõ fibronektin alapú váz domén proteinek |
| EA201590719A1 (ru) * | 2013-01-25 | 2015-12-30 | Шир Хьюман Дженетик Терапис, Инк. | Фоллистатин в лечении мышечной дистрофии дюшенна |
| WO2014187807A1 (en) | 2013-05-21 | 2014-11-27 | Arcarios B.V. | Follistatin derivatives |
| KR102132144B1 (ko) | 2014-06-04 | 2020-07-09 | 악셀레론 파마 인코포레이티드 | 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물 |
| WO2016057975A2 (en) | 2014-10-10 | 2016-04-14 | Research Institute At Nationwide Children's Hospital | Guided injections for aav gene transfer to muscle |
-
2014
- 2014-01-24 EA EA201590719A patent/EA201590719A1/ru unknown
- 2014-01-24 US US14/762,373 patent/US9957309B2/en not_active Expired - Fee Related
- 2014-01-24 EP EP14706362.2A patent/EP2948161B1/en active Active
- 2014-01-24 WO PCT/US2014/012996 patent/WO2014116981A1/en not_active Ceased
- 2014-01-24 ES ES14706362T patent/ES2715710T3/es active Active
- 2014-01-24 MX MX2015009631A patent/MX362105B/es active IP Right Grant
- 2014-01-24 AU AU2014209178A patent/AU2014209178B2/en not_active Ceased
- 2014-01-24 KR KR1020157016986A patent/KR102253597B1/ko not_active Expired - Fee Related
- 2014-01-24 CN CN201480003715.0A patent/CN104902915B/zh not_active Expired - Fee Related
- 2014-01-24 JP JP2015555353A patent/JP6475639B2/ja not_active Expired - Fee Related
- 2014-01-24 CA CA2898121A patent/CA2898121A1/en not_active Abandoned
-
2015
- 2015-07-20 IL IL240024A patent/IL240024B/en not_active IP Right Cessation
-
2018
- 2018-04-12 US US15/951,929 patent/US10723772B2/en not_active Expired - Fee Related
- 2018-10-30 JP JP2018203613A patent/JP2019059730A/ja active Pending
-
2019
- 2019-02-06 AU AU2019200797A patent/AU2019200797B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025000642A5 (enExample) | ||
| JP2022502056A5 (enExample) | ||
| JP2020040969A5 (enExample) | ||
| JP2015522576A5 (enExample) | ||
| JP2016538885A5 (enExample) | ||
| JP2018537984A5 (enExample) | ||
| JP2012529296A5 (enExample) | ||
| JP2010519931A5 (enExample) | ||
| JP2016519569A5 (enExample) | ||
| JP2016516016A5 (enExample) | ||
| CN107847565B (zh) | 用于肌肉减少症治疗的包括胰高血糖素样肽-1受体激动剂的药物组合物 | |
| JP2011511090A5 (enExample) | ||
| JP2018527941A5 (enExample) | ||
| JP2019509735A5 (enExample) | ||
| JP2019524090A5 (enExample) | ||
| JP2022546402A (ja) | ウイルス感染症を処置するための組成物及び方法 | |
| JP2014529399A5 (enExample) | ||
| JP2023527083A5 (enExample) | ||
| CN117736296A (zh) | 改造的溶瘤病毒及其用途 | |
| JP7380670B2 (ja) | Ｉｇｆ－１－暗号化ｄｎａ作製物及びｈｇｆ－暗号化ｄｎａ作製物を用いた神経病症治療 | |
| CN113321736A (zh) | 一种长效化白介素15融合蛋白及其制备方法和应用 | |
| JP7413629B2 (ja) | Ｉｇｆ－１異型体を発現させるｄｎａコンストラクトを用いた神経病症の治療 | |
| US12319714B2 (en) | Compositions and methods for treating viral infections | |
| CN121152634A (zh) | 用于治疗恶心和呕吐的方法和用途 | |
| JP2018536428A5 (enExample) |